RESUMO
OBJECTIVE: To estimate the additional healthcare system costs associated with giant cell arteritis (GCA) in the 1-year prediagnosis and postdiagnosis periods and over long-term follow-up compared to individuals with similar demographics and comorbidities without GCA. METHODS: We performed a population-based study using health administrative data. Newly diagnosed cases of GCA (between 2002 and 2017 and aged ≥ 66 years) were identified using a validated algorithm and matched 1:6 to comparators using propensity scores. Follow-up data were accrued until death, outmigration, or March 31, 2020. The costs associated with care were determined across 3 phases: the year before the diagnosis of GCA, the year after, and ongoing costs thereafter in 2021 Canadian dollars (CAD). RESULTS: The cohort consisted of 6730 cases of GCA and 40,380 matched non-GCA comparators. The average age was 77 (IQR 72-82) years and 68.2% were female. A diagnosis of GCA was associated with an increased cost of CAD $6619.4 (95% CI 5964.9-7274.0) per patient during the 1-year prediagnostic period, $12,150.3 (95% CI 11,233.1-13,067.6) per patient in the 1-year postdiagnostic phase, and $20,886.2 (95% CI 17,195.2-24,577.2) per patient during ongoing care for year 3 onward. Increased costs were driven by inpatient hospitalizations, physician services, hospital outpatient clinic services, and emergency department visits. CONCLUSION: A diagnosis of GCA was associated with increased healthcare costs during all 3 phases of care. Given the substantial economic burden, strategies to reduce the healthcare utilization and costs associated with GCA are warranted.
Assuntos
Arterite de Células Gigantes , Custos de Cuidados de Saúde , Humanos , Arterite de Células Gigantes/economia , Arterite de Células Gigantes/terapia , Feminino , Idoso , Masculino , Custos de Cuidados de Saúde/estatística & dados numéricos , Idoso de 80 Anos ou mais , Ontário , Hospitalização/economiaRESUMO
Temporal arteritis (TA) is the most common form of systemic vasculitis. Its diagnosis is based on criteria proposed by the American College of Rheumatology (1990), and its treatment is high-dose corticosteroids. Our objective is to assess the cost of diagnosing TA, and secondarily, cost-effective analysis of different diagnostic strategies (clinical, biopsy, doppler ultrasound) and therapeutic strategies (corticosteroid suspension). MATERIAL AND METHOD: Observational, retrospective study has been carried out on patients with AT (2012-2021). Demographic data, comorbidities, signs and symptoms suggestive of AT were collected. AT was diagnosed with a scoreâ¯≥â¯3 according to American College of Rheumatoloy criteria (ACR-SCORE). The costs of diagnosis and treatment modification were analysed. RESULTS: Seventy-five patients have been included, median age 77 (46-87) years. Headache, temporal pain and jaw claudication were significant for the diagnosis of TA. Patients with a halo on Doppler ultrasound and a positive biopsy have significantly elevated ESR and CRP compared to patients who do not. The cost of the AT diagnosis was 414.7 euros/patient. If we use ACR-SCOREâ¯≥â¯3-echodoppler it is 167.2â¯Ñ/patient (savings 59.6%) and ACR-SCOREâ¯≥â¯3-biopsy 339.75â¯Ñ/patient (savings 18%). If the corticosteroid was removed and a biopsy was performed, 21.6â¯Ñ/patient (94.7% savings), if the corticosteroid was removed and Doppler ultrasound was performed, 10.6â¯Ñ/patient (97.4% savings). CONCLUSIONS: Headache, temporary pain and jaw claudication are predictors of AT. Elevated ESR and CRP are predictors of positive biopsy and presence of halo on ultrasound. The uses of ACR-SCOREâ¯≥â¯3 with Doppler ultrasound or biopsy, and with corticosteroid suspension, are cost-effective.
Assuntos
Análise Custo-Benefício , Arterite de Células Gigantes , Humanos , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/economia , Estudos Retrospectivos , Idoso , Feminino , Masculino , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Ultrassonografia Doppler/economia , Biópsia/economia , Análise de Custo-EfetividadeRESUMO
Giant cell arteritis (GCA) is the most common vasculitis in adults. However, comprehensive analyses of the healthcare burden are still scarce. The aim of the study is to report the healthcare burden and cost of illness of GCA in the Friuli Venezia Giulia (FVG) region of Italy, based on a data linkage analysis. To this end, a retrospective study was conducted through the integration of many administrative health databases of the FVG region as the source of information. Cases were identified from two verified, partially overlapping sources (the rare disease registry and medical exemption database). From 2001 to 2017, 208 patients with GCA were registered. The prevalence of GCA in the population aged ⩾ 45 years as of December 31, 2017 was 27.2/100,000 inhabitants (95% CI 23.5-31.4). The mean time of observation was 4.5 ± 3.6 years. A total of 3182 visits (338 per 100 patient-years) was recorded. The most frequent specialty visits were rheumatology (n = 610, 19.2%), followed by internal medicine (n = 564, 17.7%). A total of 287 hospitalizations (30 per 100 patient-years) were reported. A total of 13,043 prescriptions (1386 per 100 patient-years) were registered. More than half of the patients were prescribed an immunosuppressive agent. The overall estimated direct healthcare cost was 2,234,070, corresponding to 2374 per patient-year. Overall, GCA is a rare disease which implies a high healthcare cost.
Assuntos
Efeitos Psicossociais da Doença , Arterite de Células Gigantes/economia , Arterite de Células Gigantes/terapia , Custos de Cuidados de Saúde , Hospitalização/economia , Imunossupressores/economia , Imunossupressores/uso terapêutico , Registro Médico Coordenado , Demandas Administrativas em Assistência à Saúde , Idoso , Idoso de 80 Anos ou mais , Bases de Dados Factuais , Custos de Medicamentos , Feminino , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/epidemiologia , Nível de Saúde , Custos Hospitalares , Humanos , Medicina Interna/economia , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Visita a Consultório Médico/economia , Prevalência , Encaminhamento e Consulta/economia , Sistema de Registros , Estudos Retrospectivos , Reumatologia/economia , Fatores de TempoRESUMO
OBJECTIVE: To assess and compare direct costs between patients with giant cell arteritis (GCA) that is associated or not associated with polymyalgia rheumatic (PMR), and to identify the additional cost drivers due to PMR. METHODS: A population-based, retrospective cohort study using the French National Health Insurance System Database was conducted. Cost analysis was performed from the French health insurance perspective and direct medical and nonmedical costs were taken into account (based on 2014 costs []). Costs were analyzed according to different components and divided into 6-month periods to assess care consumption. Longitudinal multivariate analyses, using generalized estimating equations, were used to adjust the effect of PMR on the mean cost over time. RESULTS: Analyses were performed on 100 incident patients with GCA, 54 of whom had PMR. The cumulative additional cost due to PMR was 8,801 for 3 years, and 10,532 for 5 years. The significant additional costs occurred especially during the second and third years of follow-up, amounting to 1,769 between 12 and 18 months (P = 0.02), 1,924 between 18 and 24 months (P = 0.17), 1,458 between 24 and 30 months (P = 0.08), and 1,307 between 30 and 36 months (P = 0.07). The most important cost drivers were inpatient stays, paramedic procedures, and medications. Multivariate analyses showed a significant effect of PMR on mean cost during the first 3 years of follow-up (relative risk 1.76 [95% confidence interval 1.03-2.99], P = 0.038). CONCLUSION: To our knowledge, this study is the first to accurately assess the cost of PMR care in patients with GCA and to highlight that PMR is largely responsible for the high cost of GCA.
Assuntos
Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Polimialgia Reumática/complicações , Polimialgia Reumática/economia , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , Humanos , Masculino , Estudos RetrospectivosRESUMO
OBJECTIVE: To assess and compare direct costs between giant cell arteritis (GCA) patients and matched controls and to identify incremental cost drivers. METHODS: We carried out a population-based, retrospective cohort study using the French National Health Insurance System database. Cost analysis was performed from the French health insurance perspective and took into account direct medical and nonmedical costs (2014, ). Costs were evaluated according to different cost components and divided into periods of 6 months for the accurate assessment of care consumption. Longitudinal multivariate regression analyses using generalized estimating equations were used to adjust the effect of GCA on the mean cost over time. RESULTS: Analyses were performed on 96 incident GCA patients and 563 matched controls. The cumulative incremental cost due to GCA was 6,406 and 7,236 for 3 and 5 years, respectively. Total incremental costs were significant for the first 18 months, amounting to 1,342 for the first 6 months, 1,498 between 6 and 12 months, and 1,165 between 12 and 18 months (P = 0.012, P = 0.065, and P = 0.029, respectively). The most important cost drivers were paramedical procedures, inpatient stays, medication, and medical procedures. Multivariate analysis shows the significant effect of GCA on mean cost during the first 3 years of followup (relative risk [RR] 1.72 [95% confidence interval (95% CI) 1.31-2.27], P < 0.001) with significant cost reductions (RR 0.70 [95% CI 0.49-0.99], P = 0.05) at the end of followup. CONCLUSION: This study provides an accurate assessment of GCA costs during a 5-year period and gives useful information for future cost-effectiveness studies based on new expensive biotherapies.
Assuntos
Custos e Análise de Custo/tendências , Arterite de Células Gigantes/economia , Arterite de Células Gigantes/terapia , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Custos e Análise de Custo/métodos , Feminino , Arterite de Células Gigantes/diagnóstico , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
OBJECTIVE: To determine the healthcare use and direct medical cost of giant cell arteritis (GCA) in a population-based cohort. METHODS: A well-defined, retrospective population-based cohort of Olmsted County, Minnesota, USA, residents diagnosed with GCA from 1982-2009 was compared to a matched referent cohort from the same population. Standardized cost data (inflation-adjusted to 2014 US dollars) for 1987-2014 and outpatient use data for 1995-2014 were obtained. Use and costs were compared between cohorts through signed-rank paired tests, McNemar's tests, and quantile regression models. RESULTS: Significant annual differences in outpatient costs were observed for patients with GCA in each of the first 4 years (median differences: $2085, $437, $382, $388, respectively). In adjusted analyses, median incremental cost attributed to GCA over a 5-year period was $4662. Compared with matched referent subjects, patients with GCA had higher use of laboratory visit-days annually for each of the first 3 years following incidence/index date, and increased outpatient physician visits for years 0-1, 1-2, and 3-4. Patients with GCA had significantly more radiology visit-days in years 0-1, 3-4, and 4-5, and more ophthalmologic procedures/surgery in years 0-1, 1-2, 2-3, and 4-5 compared to non-GCA. Emergency medicine visits, musculoskeletal, and cardiovascular procedures/surgery were similar between GCA and non-GCA groups throughout the study period. CONCLUSION: Direct medical outpatient costs were increased in the month preceding and in the first 4 years following GCA diagnosis. Higher use of outpatient physician, laboratory, and radiology visits, and ophthalmologic procedures among these patients accounts for the increased cost of care.
Assuntos
Serviço Hospitalar de Emergência/estatística & dados numéricos , Arterite de Células Gigantes/economia , Arterite de Células Gigantes/terapia , Custos de Cuidados de Saúde , Idoso , Idoso de 80 Anos ou mais , Serviço Hospitalar de Emergência/economia , Feminino , Humanos , Masculino , Minnesota , Pacientes Ambulatoriais , Estudos RetrospectivosRESUMO
OBJECTIVE: To estimate and project the number of people affected worldwide by giant cell arteritis (GCA) by 2050. Modeling the number of people visually impaired as a result of this disease will help establish the projected morbidity and resource burden. METHODS: A systematic literature review up to December 2013 was conducted using PubMed and ISI Web of Science. Studies reporting an incidence rate for GCA were used to model disease incident cases at regional and national levels. United Nations Population Prospect data were used for population projections. Morbidity burden was established through rates of visual impairment. The associated financial implications were calculated for the United States. RESULTS: The number of incident cases of GCA will increase secondary to an aging population. By 2050, more than 3 million people will have been diagnosed with GCA in Europe, North America, and Oceania. About 500,000 people will be visually impaired. By 2050, in the United States alone, the estimated cost from visual impairment due to GCA will exceed US$76 billion. Inpatient care for patients with active GCA will total about US$1 billion. Management of steroid-related adverse events will increase costs further, with steroid-induced fractures estimated to total US$6 billion by 2050. CONCLUSION: Projecting disease burden for GCA on a global scale allows for optimization of healthcare planning and prioritization of research domains. Additional population-based studies are required to more accurately project worldwide disease burden. Our work highlights the future global disease burden of GCA, and illustrates the associated financial implications.
Assuntos
Arterite de Células Gigantes/epidemiologia , Saúde Global/estatística & dados numéricos , Efeitos Psicossociais da Doença , Previsões , Arterite de Células Gigantes/economia , Saúde Global/economia , Custos de Cuidados de Saúde , Humanos , Incidência , PrevalênciaRESUMO
OBJECTIVES: To determine whether ischaemic manifestations of GCA are associated with pre-existing hypertension, atherosclerosis or area-level socio-economic deprivation. METHODS: We conducted an observational study of rheumatologist/ophthalmologist-diagnosed GCA in eight UK centres. The main outcome measure was ischaemic manifestations observed during active GCA: visual loss/blurring, aura, diplopia, jaw/tongue/limb claudication, cerebral/myocardial ischaemia or scalp necrosis. RESULTS: Out of 271 patients, 222 had ischaemic manifestations. Adjusted odds ratios (ORs) for the influence of hypertension and atherosclerosis were 1.6 (95% CI 0.8, 3.1) and 1.5 (0.6, 3.5). The most striking finding was an association of ischaemic manifestations with increasing Index of Deprivation 2007 score: OR 4.2 (95% CI 1.3, 13.6) for the most-deprived quartile compared with the least-deprived quartile. Similar effect sizes were seen within each recruitment centre. Deprivation was associated with smoking and negatively associated with previous polymyalgia. However, neither of these variables, nor hypertension or atherosclerosis, appeared responsible for mediating the effect of deprivation on ischaemic complications. Smoking was not associated with ischaemic manifestations. Median symptom duration before treatment was 30 days; after adjusting for symptom duration, the OR for ischaemic complications was 3.2 (95% CI 1.0, 10.8) for the most-deprived quartile compared with the least-deprived quartile. CONCLUSIONS: In GCA, area-level socio-economic deprivation was associated with ischaemic manifestations: this was not mediated by traditional cardiovascular risk factors. These findings are novel and require replication. Delay between first symptoms and treatment may play a role. Public awareness campaigns about GCA should aim especially to engage individuals living in more deprived areas to encourage early presentation and prompt treatment.
Assuntos
Aterosclerose/epidemiologia , Arterite de Células Gigantes/epidemiologia , Hipertensão/epidemiologia , Isquemia/epidemiologia , Fatores Socioeconômicos , Aterosclerose/diagnóstico , Aterosclerose/economia , Comorbidade , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/economia , Disparidades em Assistência à Saúde , Humanos , Hipertensão/diagnóstico , Hipertensão/economia , Isquemia/economia , Áreas de Pobreza , Características de Residência , Fatores de Risco , Fumar/efeitos adversos , Classe Social , Tabagismo/diagnóstico , Tabagismo/economia , Tabagismo/epidemiologia , Reino Unido/epidemiologiaRESUMO
No disponible